FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:1180-1185 November 3, 1988 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus is a promising strategy for the prevention of perinatal infections caused by group B streptococci. To explore the feasibility of this strategy, we vaccinated 40 pregnant women at a mean gestation of 31 weeks with a single 50-microgram dose of the Type III capsular polysaccharide of group B streptococcus. The only adverse effect detected was a mild local reaction in nine women (22 percent). Of the 35 women with low or unprotective antibody levels before immunization (less than 2 micrograms per milliliter), 20 (57 percent) responded to the vaccine. The geometric mean antibody level rose from 1.3 to 7.1 micrograms per milliliter four weeks after vaccination (P less than 0.02), and these levels persisted at delivery and three months post partum. Sixty-two percent of the vaccine-induced immunoglobulin in the mothers was IgG, which readily crosses the placenta. Infant antibody levels in cord serum correlated directly with maternal antibody levels at delivery (r = 0.913, P less than 0.001). Of the 25 infants born to women who responded to the vaccine, 80 percent continued to have protective levels of antibody at one month of age and 64 percent had protective levels at three months. Serum samples from infants with greater than or equal to 2 micrograms of antibody to Type III group B streptococcus per milliliter uniformly promoted efficient opsonization, phagocytosis, and bacterial killing in vitro of Type III strains. This effect could be mediated exclusively by the alternative complement pathway. Although this vaccine with an overall response rate of 63 percent is not optimally immunogenic, we conclude that maternal immunization is feasible and can provide passive immunity against systemic infection with Type III group B streptococcus in the majority of newborns. Larger trials with better vaccines will be required to evaluate the safety and clinical effectiveness of this strategy.

Source Information

Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030.

This article has been cited by other articles:

• Yang, H.-H., Mascuch, S. J., Madoff, L. C., Paoletti, L. C. (2008). Recombinant Group B Streptococcus Alpha-Like Protein 3 Is an Effective Immunogen and Carrier Protein. CVI 15: 1035-1041 [Abstract] [Full Text]  
• Yang, H.-H., Madoff, L. C., Guttormsen, H.-K., Liu, Y.-D., Paoletti, L. C. (2007). Recombinant Group B Streptococcus Beta C Protein and a Variant with the Deletion of Its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines. Infect. Immun. 75: 3455-3461 [Abstract] [Full Text]  
• Liang, Y.-C., Yeh, J.-Y., Ou, B.-R. (2007). Effect of maternal myostatin antibody on offspring growth performance and body composition in mice. J. Exp. Biol. 210: 477-483 [Abstract] [Full Text]  
• Maione, D., Margarit, I., Rinaudo, C. D., Masignani, V., Mora, M., Scarselli, M., Tettelin, H., Brettoni, C., Iacobini, E. T., Rosini, R., D'Agostino, N., Miorin, L., Buccato, S., Mariani, M., Galli, G., Nogarotto, R., Dei, V. N., Vegni, F., Fraser, C., Mancuso, G., Teti, G., Madoff, L. C., Paoletti, L. C., Rappuoli, R., Kasper, D. L., Telford, J. L., Grandi, G. (2005). Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. Science 309: 148-150 [Abstract] [Full Text]  
• Offit, P. A. (2005). Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?. Health Aff (Millwood) 24: 622-630 [Abstract] [Full Text]  
• Larsson, C., Holmgren, J., Lindahl, G., Bergquist, C. (2004). Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection. Infect. Immun. 72: 1184-1187 [Abstract] [Full Text]  
• McDonald, L. C., Bryant, K., Snyder, J. (2003). Peripartum Transmission of Penicillin-Resistant Streptococcus pneumoniae. J. Clin. Microbiol. 41: 2258-2260 [Abstract] [Full Text]  
• Baker, C J, Edwards, M S (2003). Group B streptococcal conjugate vaccines. Arch. Dis. Child. 88: 375-378 [Abstract] [Full Text]  
• Pozdnyakova, O., Guttormsen, H.-K., Lalani, F. N., Carroll, M. C., Kasper, D. L. (2003). Impaired Antibody Response to Group B Streptococcal Type III Capsular Polysaccharide in C3- and Complement Receptor 2-Deficient Mice. J. Immunol. 170: 84-90 [Abstract] [Full Text]  
• Martin, D., Rioux, S., Gagnon, E., Boyer, M., Hamel, J., Charland, N., Brodeur, B. R. (2002). Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein. Infect. Immun. 70: 4897-4901 [Abstract] [Full Text]  
• Guttormsen, H.-K., Baker, C. J., Nahm, M. H., Paoletti, L. C., Zughaier, S. M., Edwards, M. S., Kasper, D. L. (2002). Type III Group B Streptococcal Polysaccharide Induces Antibodies That Cross-React with Streptococcus pneumoniae Type 14. Infect. Immun. 70: 1724-1738 [Abstract] [Full Text]  
• Hughes, M. J. G., Moore, J. C., Lane, J. D., Wilson, R., Pribul, P. K., Younes, Z. N., Dobson, R. J., Everest, P., Reason, A. J., Redfern, J. M., Greer, F. M., Paxton, T., Panico, M., Morris, H. R., Feldman, R. G., Santangelo, J. D. (2002). Identification of Major Outer Surface Proteins of Streptococcus agalactiae. Infect. Immun. 70: 1254-1259 [Abstract] [Full Text]  
• Erdogan, S., Fagan, P. K., Talay, S. R., Rohde, M., Ferrieri, P., Flores, A. E., Guzman, C. A., Walker, M. J., Chhatwal, G. S. (2002). Molecular Analysis of Group B Protective Surface Protein, a New Cell Surface Protective Antigen of Group B Streptococci. Infect. Immun. 70: 803-811 [Abstract] [Full Text]  
• Brodeur, B. R., Boyer, M., Charlebois, I., Hamel, J., Couture, F., Rioux, C. R., Martin, D. (2000). Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity. Infect. Immun. 68: 5610-5618 [Abstract] [Full Text]  
• Guttormsen, H.-K., Sharpe, A. H., Chandraker, A. K., Brigtsen, A. K., Sayegh, M. H., Kasper, D. L. (1999). Cognate Stimulatory B-Cell-T-Cell Interactions Are Critical for T-Cell Help Recruited by Glycoconjugate Vaccines. Infect. Immun. 67: 6375-6384 [Abstract] [Full Text]  
• Malhotra, I., Mungai, P., Wamachi, A., Kioko, J., Ouma, J. H., Kazura, J. W., King, C. L. (1999). Helminth- and Bacillus Calmette-Guerin-Induced Immunity in Children Sensitized In Utero to Filariasis and Schistosomiasis. J. Immunol. 162: 6843-6848 [Abstract] [Full Text]  
• Gravekamp, C., Kasper, D. L., Paoletti, L. C., Madoff, L. C. (1999). Alpha C Protein as a Carrier for Type III Capsular Polysaccharide and as a Protective Protein in Group B Streptococcal Vaccines. Infect. Immun. 67: 2491-2496 [Abstract] [Full Text]  
• Bhushan, R., Anthony, B. F., Frasch, C. E. (1998). Estimation of Group B Streptococcus Type III Polysaccharide-Specific Antibody Concentrations in Human Sera Is Antigen Dependent. Infect. Immun. 66: 5848-5853 [Abstract] [Full Text]  
• Schuchat, A. (1998). Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms. Clin. Microbiol. Rev. 11: 497-513 [Abstract] [Full Text]  
• Guttormsen, H.-K., Wetzler, L. M., Finberg, R. W., Kasper, D. L. (1998). Immunologic Memory Induced by a Glycoconjugate Vaccine in a Murine Adoptive Lymphocyte Transfer Model. Infect. Immun. 66: 2026-2032 [Abstract] [Full Text]  
• Kozel, T. R., deJong, B. C. H., Grinsell, M. M., MacGill, R. S., Wall, K. K. (1998). Characterization of Anticapsular Monoclonal Antibodies That Regulate Activation of the Complement System by the Cryptococcus neoformans Capsule. Infect. Immun. 66: 1538-1546 [Abstract] [Full Text]  
• King, C. L., Malhotra, I., Mungai, P., Wamachi, A., Kioko, J., Ouma, J. H., Kazura, J. W. (1998). B Cell Sensitization to Helminthic Infection Develops In Utero in Humans. J. Immunol. 160: 3578-3584 [Abstract] [Full Text]  
• Pincus, S. H., Smith, M. J., Jennings, H. J., Burritt, J. B., Glee, P. M. (1998). Peptides That Mimic the Group B Streptococcal Type III Capsular Polysaccharide Antigen. J. Immunol. 160: 293-298 [Abstract] [Full Text]  
• Li, J., Kasper, D. L., Ausubel, F. M., Rosner, B., Michel, J. L. (1997). Inactivation of the alpha  C protein antigen gene, bca, by a novel shuttle/suicide vector results in attenuation of virulence and immunity in group B Streptococcus. Proc. Natl. Acad. Sci. USA 94: 13251-13256 [Abstract] [Full Text]  
• Farley, M. M., Harvey, C., Stull, T., Smith, J. D., Schuchat, A., Wenger, J. D., Stephens, D. S. (1993). A Population-Based Assessment of Invasive Disease Due to Group B Streptococcus in Nonpregnant Adults. NEJM 328: 1807-1811 [Abstract] [Full Text]  
• Wessels, M. R., Kasper, D. L. (1993). The Changing Spectrum of Group B Streptococcal Disease. NEJM 328: 1843-1844 [Full Text]  
• (1988). FIRST STEPS TOWARDS A VACCINE FOR GROUP B STREPTOCOCCI IN PREGNANT WOMEN. JWatch General 1988: 5-5 [Full Text]